Related Experiment Videos
Neoadjuvant therapy for high-risk localized prostate cancer
1Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Dana 1230, 44 Binney Street, Boston, MA 02115, USA. evan_yu@cfci.harvard.edu
Current Oncology Reports
|April 2, 2003
Summary
High-risk prostate cancer patients face recurrence despite treatment. New research explores neoadjuvant hormonal manipulation, chemotherapy, and targeted agents to improve outcomes for localized prostate cancer.
Area of Science:
- Oncology
- Urology
Background:
- Patients with high-risk localized prostate cancer (T3 stage, Gleason score 8-10, PSA > 20 ng/mL) have a high risk of recurrence after local therapy.
- While hormonal therapy offers palliative benefits for metastatic prostate cancer, its survival benefit in the neoadjuvant setting for locally advanced disease remains unproven.
Purpose of the Study:
- To review the current literature on neoadjuvant therapies for high-risk localized prostate cancer.
- To explore the evolving role of chemotherapy and novel molecular targeted agents in this patient population.
Main Methods:
- Literature review of recent studies on neoadjuvant hormonal manipulation, chemotherapy, and targeted agents.
- Analysis of clinical trial data investigating these treatment modalities in high-risk prostate cancer.
Main Results:
- Hormonal therapy has not demonstrated a survival benefit prior to surgery for locally advanced disease.
- Chemotherapy's role in hormone-refractory prostate cancer is under active investigation, with new evidence potentially challenging historical beliefs.
- Ongoing trials are evaluating chemotherapy in the neoadjuvant setting for high-risk prostate cancer.
Conclusions:
- Neoadjuvant hormonal manipulation, chemotherapy, and molecular targeted agents are being investigated for high-risk localized prostate cancer.
- Further research is needed to establish the efficacy and optimal use of these neoadjuvant strategies to improve recurrence rates and survival.